Blood-based screening for CRC may be better than no screening at all, but it can't replace colonoscopy as the gold standard, according to two new modeling studies and an expert consensus commentary.
New research confirms racial disparities in survival outcomes and representation in clinical trials among Black and White women with a common subtype of endometrial cancer.
A meta-analysis confirms that neoadjuvant chemoimmunotherapy improves survival outcomes in most patients with resectable NSCLC, except for overall survival in patients with baseline PD-L1 below 1%.